
NGM Biopharmaceuticals, Inc. (NGM Bio) (NASDAQ:NGM) initiated a Phase 1/1b clinical study of its drug candidate NGM438 for the treatment of patients with advanced solid tumors.
This clinical study initiation process brings all three of NGM Bio's wholly-owned myeloid reprogramming product candidates NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, NGM831, an ILT3 antagonist antibody, and NGM438 now into the clinic.